Close Menu

NEW YORK – Cambridge, UK-based cancer startup Biofidelity said on Thursday that it has raised $12 million in a Series A financing round.

The firm will use the funding to accelerate the development and clinical validation of oncology panels for treatment selection and patient monitoring, with an initial focus on non-small cell lung cancer.

The financing round was led by BlueYard Capital, with additional funding from investors including Longwall Ventures and Agilent Technologies.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.